Samsung's Ontruzant Becomes First Trastuzumab Biosimilar Approved In EU

 
• By Jung Won Shin

Samsung Bioepis is poised to grab the leading position in the trastuzumab biosimilar market in Europe as its biosimilar Ontruzant gets the European Commission's approval ahead of the competition.

Samsung Bioepis
Samsung Bioepis researchers conducting a study • Source: Samsung Bioepis

More from Biosimilars

More from Products